This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA®: As effective as a carbapenem in hospitalised patients with aerobic Gram-negative cIAIs15, cUTIs16 or HAP, including VAP17

Overall Risk Factors

HAP/ VAP Patient Profile

cIAI Patient Profile

cUTI Patient Profile

Identifying patients with HAP/VAP at high-risk of MDR Gram-negative infections

“It is critical for clinicians to identify patients at risk of multi-drug resistance from the onset of infection”18

Patient Profile: Charles – 78-year-old male*

*The example described here is not an actual patient, but rather a fictious representation of a scenario for which ZAVICEFTA could be considered. 

Risk Factors in a HAP/VAP Patient2-4,21

Patient History:

  • Smoker for >45 years
  • Immunosuppressed
  • Frequent travel
  • Chronic renal insufficiency
  • Recent fall at home

Symptoms (developed after 4 days in hospital following fall at home):

  • Wheezing
  • Purulent sputum
  • Leukocytosis
  • Tachypnea
  • Cough
  • Sweating

Diagnosis:

  • Hospital-acquired pneumonia

Suspected Pathogens:

  • MDR Gram-negative pathogens including K. pneumoniae, E. coli, P. aeruginosa 
  • Based on patient’s disease severity, there is concern about potential involvement of carbapenem-resistant strains. 

Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage.

Access dosing guide

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP​

View Phase III trial​


Abbreviations

​​​​​​​​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae;  MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa;  CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;

References
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65
  3. Miller BM, et al. Am J Infect Control 2016;44:134–7
  4. De Waele J, et al. Intensive Care Med 2018;44:189–96
  5. Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23
  6. Harris AD, et al. Emerg Infect Dis 2007;13:1144–9
  7. Timsit JF, et al. Intensive Care Med 2019;45:172–89 
  8. Bonine NG, et al. Am J Med Sci 2019;357:102–10
  9. Raman G, et al. BMC Infect Dis 2015;15:395
  10. Kang CI, et al. Clin Infect Dis 2003;37:745–51
  11. Scheuherman O, et al. Infect Control Hosp Epidemiol 2018;39:660–7
  12. Daikos GL, et al. Antimicrob Agents Chemother 2014;58:2322–8
  13. Navarro-San Francisco C, et al. Clin Microbiol Infect 2012;19:E72–9
  14. Zarkotou O, et al. Clin Microbiol Infect 2011;17:1798–803
  15. Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9
  16. Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62
  17. Torres A, et al. Lancet Infect Dis 2017;Epub
  18. Micek ST, et al. Crit Care 2015;19:219
  19. Sartelli M, et al. World J Emerg Surg 2017;12:22
  20. Flores-Mireles AL, et al. Nat Rev Microbiol 2015;13:269–84 ​​​
  21. Torres A, et al. European Respiratory Journal 2017 50: 1700582;
  22. Sartelli, et al.  CIAO study. World J Emerg Surg 2012;5-6
  23. Gomila A, et al. Infection and Drug Resistance 2018:11 2571–2581
  24. Zilberberg M D, et al. Antimicrob Agents Chemother 2020;63:e00346-20
PP-ZVA-GBR-0840. June 2021

Learn more about the tolerability data of Zavicefta from four phase III clinical trials.

View safety profile

KOL Video 2019

Professor Francesco G. De Rosa, Prof. of Infectious Diseases (Italy, Professor Philip Montravers, Anaestheisa and Critical Care Medicine (France) and Dr Paula Ramirez, Critical Care Department (Spain) discuss high-risk patients and early treatment of patients with suspected MDR Gram-negative infections in their clinical practice, and their experience using ZAVICEFTA. 

Card CTA

** This is an optional area where footnotes can live.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No